Effects of charge on antibody tissue distribution and pharmacokinetics

…, DB Tesar, K Mukhyala, FP Theil, PJ Fielder… - Bioconjugate …, 2010 - ACS Publications
Antibody pharmacokinetics and pharmacodynamics are often governed by biological processes
such as binding to antigens and other cognate receptors. Emphasis must also be placed…

Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets

PJ Fielder, AL Gurney, E Stefanich, M Marian… - 1996 - ashpublications.org
The involvement of platelets and the c-mpl receptor in the regulation of thrombopoietin (TPO)
plasma concentrations and tissue mRNA levels was investigated in both normal mice and …

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?

R Deng, S Iyer, FP Theil, DL Mortensen, PJ Fielder… - MAbs, 2011 - Taylor & Francis
The pharmacokinetics (PK) of therapeutic antibodies is determined by target and non-target
mediated mechanisms. These antibody-specific factors need to be considered during …

Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody–drug conjugates in rats

…, J Tibbitts, S Kaur, FP Theil, PJ Fielder… - Bioconjugate …, 2011 - ACS Publications
Antibody–drug conjugates (ADCs) are designed to combine the exquisite specificity of
antibodies to target tumor antigens with the cytotoxic potency of chemotherapeutic drugs. In …

[HTML][HTML] The little women of Loja—growth Hormone–Receptor deficiency in an inbred population of southern Ecuador

…, JG Aguirre, RG Rosenfeld, PJ Fielder - New England Journal …, 1990 - Mass Medical Soc
Background and Methods. Laron-type dwarfism, which is characterized by the clinical
appearance of isolated growth hormone deficiency with elevated serum levels of growth hormone …

Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration

…, KJ Cowan, DM Danilenko, AL Daugherty, PJ Fielder… - MAbs, 2012 - Taylor & Francis
Subcutaneous (SC) delivery is a common route of administration for therapeutic monoclonal
antibodies (mAbs) with pharmacokinetic (PK)/pharmacodynamic (PD) properties requiring …

Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice

…, E Mai, MX Sliwkowski, PJ Fielder, J Tibbitts - … of pharmacokinetics and …, 2010 - Springer
Trastuzumab-DM1 (T-DM1) is a novel antibody–drug conjugate under investigation for the
treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast …

Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-α antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys

…, LE DeForge, FP Theil, HB Lowman, PJ Fielder… - Drug Metabolism and …, 2010 - ASPET
The neonatal Fc receptor (FcRn) plays a critical role in maintaining homeostasis of IgG
antibodies. Recent studies have shown that the FcRn-IgG interaction can be modulated to alter …

Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics

D Bumbaca, CA Boswell, PJ Fielder, LA Khawli - The AAPS journal, 2012 - Springer
Monoclonal antibodies are increasingly being developed to treat multiple disease areas,
including those related to oncology, immunology, neurology, and ophthalmology. There are …

Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model

…, M Sliwkowski, J Tibbitts, FP Theil, PJ Fielder… - Molecular cancer …, 2012 - AACR
Both human epidermal growth factor receptor 2 (HER-2/neu) and VEGF overexpression
correlate with aggressive phenotypes and decreased survival among breast cancer patients. …